Seek Returns

LLY vs. MRK: Eli Lilly vs. Merck Stock Comparison

How do Eli Lilly (LLY) and Merck (MRK) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Eli Lilly (LLY) and Merck (MRK) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Company profile comparison for Eli Lilly (LLY) and Merck (MRK)
Profile ItemLLYMRK
NameEli Lilly and CompanyMerck & Co., Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticalsPharmaceuticals
GICS Sub-IndustryPharmaceuticalsPharmaceuticals
Market Capitalization1,285.79 billion USD364.26 billion USD
CurrencyUSDUSD
ExchangeNYSENYSE
Listing DateJune 1, 1972January 2, 1962
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

LLY
MRK
GSPC
Loading price history…
Eli Lilly (LLY) vs. Merck (MRK), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Eli Lilly (LLY) and Merck (MRK). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Eli Lilly (LLY) and Merck (MRK). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Eli Lilly (LLY) and Merck (MRK)
MetricLLYMRK
Total Return (1Y)42.18%63.67%
Total Return (3Y, Annualized)34.03%16.47%
Total Return (5Y, Annualized)42.16%15.44%

Risk Profile

Drawdown History

LLY
MRK
GSPC
Loading price history…
Eli Lilly (LLY) vs. Merck (MRK), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Eli Lilly (LLY) and Merck (MRK). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Eli Lilly (LLY) and Merck (MRK)
MetricLLYMRK
Volatility (1Y, Annualized)35.25%29.83%
Beta (5Y)0.390.11
Max Drawdown (5Y)-34.48%-43.44%
Avg. Volume (3M)2.56M10.19M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
LLY and MRK are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Eli Lilly (LLY) and Merck (MRK)
MetricLLYMRK
Sharpe Ratio (1Y)1.061.98
Sortino Ratio (1Y)1.793.56

Profitability

ROE (TTM)

Eli Lilly (LLY) at 86.02% sits in the top ROE quartile, while Merck (MRK) at 5.06% is closer to the peer norm — stronger capital efficiency for LLY.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

86.02%

Max
109.18%
LLY
86.02%
Q3
6.99%
Median
-27.11%
Q1
-63.32%
Min
-153.84%

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.06%

Max
109.18%
Q3
6.99%
MRK
5.06%
Median
-27.11%
Q1
-63.32%
Min
-153.84%
Loading chart…
Eli Lilly (LLY) vs. Merck (MRK): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Eli Lilly (LLY) at 31.90% converts revenue to bottom-line profit above its industry’s benchmark range, while Merck (MRK) at 3.64% keeps roughly the typical share for its industry.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.90%

LLY
31.90%
Max
20.27%
Q3
4.98%
Median
0.00%
Q1
-5.28%
Min
-18.66%

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.64%

Max
20.27%
Q3
4.98%
MRK
3.64%
Median
0.00%
Q1
-5.28%
Min
-18.66%
Loading chart…
Eli Lilly (LLY) vs. Merck (MRK): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Eli Lilly (LLY) at 51.25% and Merck (MRK) at 35.16% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

51.25%

Max
80.14%
LLY
51.25%
Q3
12.89%
Median
0.00%
Q1
-69.33%
Min
-189.53%

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.16%

Max
80.14%
MRK
35.16%
Q3
12.89%
Median
0.00%
Q1
-69.33%
Min
-189.53%
Loading chart…
Eli Lilly (LLY) vs. Merck (MRK): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Eli Lilly (LLY) and Merck (MRK)
MetricLLYMRK
ROE (TTM)86.02%5.06%
ROA (TTM)21.06%11.29%
Net Margin (TTM)31.90%3.64%
Operating Margin (TTM)51.25%35.16%
Gross Margin (TTM)83.63%75.20%

Growth

Revenue Growth

Both Eli Lilly (LLY) at 44.70% and Merck (MRK) at 1.31% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Eli Lilly (LLY) vs. Merck (MRK): A comparison of their Revenue Growth across different time periods.

EPS Growth

Eli Lilly (LLY) at 95.99% sits in the top EPS growth quartile, while Merck (MRK) at 8.01% is closer to the peer norm — faster per-share earnings growth for LLY.

Loading chart…
Eli Lilly (LLY) vs. Merck (MRK): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Eli Lilly (LLY) and Merck (MRK)
MetricLLYMRK
Revenue Growth (YoY)44.70%1.31%
Revenue Growth (3Y CAGR)31.69%3.12%
EPS Growth (YoY)95.99%8.01%
EPS Growth (3Y CAGR)51.71%8.43%

Financial Strength

Current Ratio (MRQ)

Both Eli Lilly (LLY) at 1.39 and Merck (MRK) at 1.35 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.39

Max
23.95
Q3
11.76
Median
5.04
Q1
2.44
LLY
1.39
Min
0.10

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.35

Max
23.95
Q3
11.76
Median
5.04
Q1
2.44
MRK
1.35
Min
0.10
Loading chart…
Eli Lilly (LLY) vs. Merck (MRK): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Eli Lilly (LLY) at 1.23 and Merck (MRK) at 1.20 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.23

Max
1.44
LLY
1.23
Q3
0.66
Median
0.15
Q1
0.02
Min
0.00

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.20

Max
1.44
MRK
1.20
Q3
0.66
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Eli Lilly (LLY) vs. Merck (MRK): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Eli Lilly (LLY) and Merck (MRK)
MetricLLYMRK
Current Ratio (MRQ)1.391.35
Debt / Equity (MRQ)1.231.20
Net Debt / EBITDA0.961.50

Dividends

Dividend Yield (TTM)

Both Eli Lilly (LLY) at 0.47% and Merck (MRK) at 2.29% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.47%

LLY
0.47%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.29%

MRK
2.29%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Eli Lilly (LLY) vs. Merck (MRK): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Merck (MRK) reports payout ratio above 100% at 343.43%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Eli Lilly (LLY) reports 21.71%, ranking against industry peers normally.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.71%

LLY
21.71%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

343.43%

MRK
343.43%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Eli Lilly (LLY) vs. Merck (MRK): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Eli Lilly (LLY) and Merck (MRK)
MetricLLYMRK
Dividend Yield (TTM)0.47%2.29%
Dividend Payout Ratio (TTM)21.71%343.43%

Valuation

P/E Ratio (TTM)

Both look expensive on trailing earnings: Eli Lilly (LLY) at 46.85 sits in the richer P/E ratio quartile, and Merck (MRK) at 149.25 is richer still, above its industry range.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

46.85

Max
89.00
LLY
46.85
Q3
46.79
Median
27.68
Q1
14.13
Min
0.06

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

149.25

MRK
149.25
Max
89.00
Q3
46.79
Median
27.68
Q1
14.13
Min
0.06
Loading chart…
Eli Lilly (LLY) vs. Merck (MRK): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Eli Lilly (LLY) at 14.87 and Merck (MRK) at 5.41 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.87

Max
48.61
Q3
22.40
LLY
14.87
Median
6.95
Q1
3.09
Min
0.01

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.41

Max
48.61
Q3
22.40
Median
6.95
MRK
5.41
Q1
3.09
Min
0.01
Loading chart…
Eli Lilly (LLY) vs. Merck (MRK): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Merck (MRK) at 8.12 sits in the upper P/B ratio quartile, and Eli Lilly (LLY) at 31.95 prices even higher, above its industry range.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.95

LLY
31.95
Max
13.20
Q3
6.63
Median
3.27
Q1
1.80
Min
-5.40

MRK

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.12

Max
13.20
MRK
8.12
Q3
6.63
Median
3.27
Q1
1.80
Min
-5.40
Loading chart…
Eli Lilly (LLY) vs. Merck (MRK): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Eli Lilly (LLY) and Merck (MRK)
MetricLLYMRK
P/E Ratio (TTM)46.85149.25
P/S Ratio (TTM)14.875.41
P/B Ratio (MRQ)31.958.12
Free Cash Flow Yield (TTM)0.73%3.85%